Migraine Drugs Market to grow by USD 1.1399 billion from 2022 to 2027 | Increase in the number of patients suffering from migraine to boost the market- Technavio.

NEW YORK, Aug. 24, 2023 /PRNewswire/ -- The migraine drugs market is estimated to grow by USD 1.1399 billion from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 6.05%. The growth momentum will progress during the forecast period. North America held the largest share of the global market in 2022, and the market in the region is estimated to witness an incremental growth of 37%. The main factor driving the growth of the market in the region is the presence of a well-established healthcare system that provides high-quality migraine treatments mainly through clinics and hospitals. The increase in healthcare costs in countries like the US and Canada is another factor that will support the growth of the migraine drug market in the region. In addition, to increase the commercialization of migraine drugs in the region, several companies are focusing on strategic partnerships. Hence, these factors are expected to drive segment growth during the forecast period. For more insights on the historic period (2017 to 2021) and forecast market size (2023 to 2027) - Request a sample report

What's New?

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions 
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial  - buy the report!

Migraine Drugs Market - Segmentation Assessment
Segment Overview
Technavio has segmented the market based on end-user (hospitals, retail, and online), type (preventive and abortive), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). 

• The market share growth by the hospitals segment will be significant during the forecast period. The increasing prevalence and diagnosis of migraine and the growing number of public and private specialty hospitals and clinic segments are influenced by the clinics that provide migraine medication. In addition, large hospitals and clinics have state-of-the-art healthcare infrastructure, which means they can purchase high-quality healthcare consumables and products in bulk. Hence, these factors are expected to drive segment growth during the forecast period.

Insights on the market contribution of various segments, including country and region wise historic data (2017 to 2021), and forecast market size (2023 to 2027) - Download a Sample Report

Migraine Drugs Market – Market Dynamics

Key Driver

The increase in the number of patients suffering from migraine is a key factor driving market growth. Migraine headaches are a very common neurological condition worldwide. It's more common in North America, and migraines can also be caused by taking too much pain medication. Some other triggers include sleep deprivation, hunger, migraines, weather changes, overstimulation of the senses, and stress. Migraines often begin in childhood or in early adulthood. In addition, women are more prone to migraines and less responsive to migraine treatment. Hence, the increasing number of migraine patients is expected to drive market growth during the forecast period.

Major Trends  - The rising advances in migraine drugs are a major trend in the market.

Significant Challenge - The lack of awareness and proper diagnosis of migraine is a significant challenge restricting market growth. 

Insights on Market Drivers, trends, & Challenges, historic period(2017 to 2021) and forecast period(2023 to 2027)- Request a sample report!

What are the key data covered in this Migraine Drugs Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the migraine drugs market between 2023 and 2027
• Precise estimation of the size of the migraine drugs market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the migraine drugs market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of migraine drugs market companies

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The duchenne muscular dystrophy (DMD) therapeutics market is estimated to grow by USD 2,397.67 million at a CAGR of 21.2% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by type (biologics and small molecules), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of World (ROW)). The high unmet need among patients with Duchenne muscular dystrophy (DMD) is a key factor driving market growth during the forecast period.

The photodynamic therapy market is estimated to grow by USD 2,053.68 million at a CAGR of 8.22% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by application (cancer, actinic keratosis, psoriasis, acne, and others), product (photosensitizer drugs, and photodynamic therapy devices), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Early detection of cancer is a key factor driving market growth during the forecast period.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by end-user

7 Market Segmentation by Type

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio